Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2024-10-18
Target enrollment:
Participant gender:
Summary
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche
of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1
blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients
with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with
Auto-HSCT and maintenance with BV + PD-blockade
1?